| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $13,250 | 1 | 33 |
Sells | $4,941,713 | 2 | 67 |
| Alfieri Michael | Principal Financial Officer | 1 | $13,250 | 0 | $0 | $13,250 |
| Machatha Stephen | Chief Development Officer | 0 | $0 | 1 | $113,713 | $-113,713 |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 0 | $0 | 1 | $4.83M | $-4.83M |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Over the last 12 months, insiders at Aldeyra Therapeutics, Inc. have bought $13,250 and sold $4.94M worth of Aldeyra Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aldeyra Therapeutics, Inc. have bought $9.56M and sold $3.42M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Alfieri Michael (Principal Financial Officer) — $13,250.
The last purchase of 2,500 shares for transaction amount of $13,250 was made by Alfieri Michael (Principal Financial Officer) on 2025‑08‑13.
| 2025-08-13 | Alfieri Michael | Principal Financial Officer | 2,500 0.0041% | $5.30 | $13,250 | -2.37% | ||
| 2025-08-11 | Sale | Machatha Stephen | Chief Development Officer | 22,073 0.0362% | $5.15 | $113,713 | -0.05% | |
| 2025-04-03 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 3.4M 5.6943% | $1.42 | $4.83M | +250.70% | |
| 2024-08-12 | Sale | Machatha Stephen | Chief Development Officer | 16,041 0.0272% | $4.74 | $75,975 | +8.84% | |
| 2024-08-12 | Sale | Greenberg Bruce | See Remarks | 10,834 0.0184% | $4.74 | $51,313 | +8.84% | |
| 2024-04-05 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 37,712 0.0643% | $4.74 | $178,755 | +6.46% | ||
| 2024-04-04 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 140,281 0.2374% | $4.67 | $655,112 | +7.26% | ||
| 2024-04-03 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 309,847 0.5185% | $4.09 | $1.27M | +20.96% | ||
| 2024-04-02 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 186,051 0.3061% | $3.44 | $640,015 | +41.41% | ||
| 2024-04-01 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 8,374 0.0141% | $3.25 | $27,216 | +53.52% | ||
| 2024-03-12 | Sale | Brady Todd C | President and CEO | 85,324 0.147% | $3.05 | $260,238 | +62.13% | |
| 2024-03-12 | Sale | Machatha Stephen | Chief Development Officer | 11,537 0.0206% | $3.16 | $36,503 | +62.13% | |
| 2024-03-11 | Sale | Brady Todd C | President and CEO | 97,914 0.1675% | $3.27 | $320,521 | +49.85% | |
| 2024-03-11 | Sale | Machatha Stephen | Chief Development Officer | 18,231 0.0324% | $3.41 | $62,102 | +49.85% | |
| 2024-03-11 | Sale | Greenberg Bruce | See Remarks | 13,201 0.0235% | $3.41 | $44,968 | +49.85% | |
| 2023-10-18 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 306,499 0.5276% | $1.74 | $533,308 | +112.14% | |
| 2023-10-16 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 2.45M 3.6657% | $1.60 | $3.92M | +98.63% | |
| 2023-04-12 | Miller-Rich Nancy | director | 509 0.0009% | $10.13 | $5,156 | -45.04% | ||
| 2022-08-09 | EDELMAN JOSEPH | 15,000 0.027% | $7.85 | $117,750 | -4.83% | |||
| 2022-08-08 | EDELMAN JOSEPH | 97,000 0.1669% | $7.24 | $702,280 | -1.53% |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 5875851 9.77% | $27.62M | 18 | 3 | +10.5% |
| Machatha Stephen | Chief Development Officer | 221799 0.3688% | $1.04M | 0 | 4 | |
| Alfieri Michael | Principal Financial Officer | 2500 0.0042% | $11,750.00 | 1 | 0 | |
| EDELMAN JOSEPH | 11350085 18.8723% | $53.35M | 9 | 0 | +19.39% | |
| Brady Todd C | President and CEO | 1471298 2.4464% | $6.92M | 11 | 2 | +8.57% |
| Greenberg Bruce | See Remarks | 126382 0.2101% | $593,995.40 | 0 | 2 | |
| DOUGLAS RICHARD | director | 125000 0.2078% | $587,500.00 | 7 | 0 | +43% |
| Reed Joshua | Chief Financial Officer | 35774 0.0595% | $168,137.80 | 1 | 0 | +5.74% |
| JOYCE MARTIN JOSEPH | 23967 0.0399% | $112,644.90 | 5 | 0 | +39.89% | |
| Bronstein Ben | director | 18644 0.031% | $87,626.80 | 3 | 0 | +4.27% |
| Clark David J | Chief Medical Officer | 17878 0.0297% | $84,026.60 | 1 | 0 | +8.52% |
| Clarke C. Boyd | director | 15500 0.0258% | $72,850.00 | 2 | 0 | +69.28% |
| Phillips Gary M. | director | 9375 0.0156% | $44,062.50 | 1 | 0 | +20.83% |
| TREU JESSE I | director | 8763 0.0146% | $41,186.10 | 0 | 1 | |
| Walker Neal | director | 6250 0.0104% | $29,375.00 | 1 | 0 | +20.83% |
| McMullin David | Chief Commerical Officer | 6148 0.0102% | $28,895.60 | 1 | 0 | +5.74% |
| Tulipano Stephen J | Chief Financial Officer | 3333 0.0055% | $15,665.10 | 1 | 0 | +0.98% |
| Miller-Rich Nancy | director | 922 0.0015% | $4,333.40 | 2 | 0 | <0.0001% |
Aldeyra Therapeutics, Inc. (ALDX) | $87,639,490 | 62 | 18.37% | $282.67M |
$64,487,106 | 32 | -22.92% | $256.4M | |
$79,019,806 | 27 | 7.24% | $316.68M | |
$1,842,003 | 22 | -0.74% | $310.93M | |
$1,750,547 | 21 | 43.09% | $301.47M | |
$14,865,077 | 18 | -28.56% | $292.62M | |
$17,741,707 | 13 | 30.23% | $262.69M | |
$10,143,329 | 12 | 11.84% | $311.47M | |
$57,263,116 | 11 | -8.37% | $321.36M | |
$14,995,689 | 8 | 3.76% | $318.51M | |
$603,645 | 8 | 57.40% | $249.66M | |
$122,405 | 7 | -9.25% | $248.44M | |
$17,675,244 | 7 | 92.20% | $267.07M | |
$46,740 | 5 | -73.90% | $268.21M | |
$58,352 | 4 | -43.78% | $332.51M | |
$4,888,000 | 3 | -20.50% | $246.55M | |
$193,101 | 3 | -25.20% | $281.6M | |
$2,720,023 | 3 | -11.76% | $314.12M | |
$102,796 | 1 | -21.40% | $247.67M |
| Increased Positions | 82 | +76.64% | 7M | +19.55% |
| Decreased Positions | 41 | -38.32% | 2M | -4.77% |
| New Positions | 28 | New | 983,480 | New |
| Sold Out Positions | 16 | Sold Out | 626,903 | Sold Out |
| Total Postitions | 148 | +38.32% | 39M | +14.78% |
| Knoll Capital Management, Llc | $30,006.00 | 9.13% | 5.48M | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $28,618.00 | 8.7% | 5.22M | +1M | +28.89% | 2025-09-30 |
| Blackrock, Inc. | $20,851.00 | 6.34% | 3.8M | -47,181 | -1.23% | 2025-09-30 |
| Vanguard Group Inc | $19,683.00 | 5.99% | 3.59M | +90,276 | +2.58% | 2025-09-30 |
| Ardsley Advisory Partners Lp | $10,412.00 | 3.17% | 1.9M | -150,000 | -7.32% | 2025-09-30 |
| Aqr Capital Management Llc | $8,249.00 | 2.51% | 1.51M | +31,548 | +2.14% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $7,562.00 | 2.3% | 1.38M | +892,171 | +182.94% | 2025-09-30 |
| Kingdon Capital Management, L.L.C. | $7,298.00 | 2.22% | 1.33M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $6,447.00 | 1.96% | 1.18M | +29,823 | +2.6% | 2025-09-30 |
| Kennedy Capital Management Llc | $6,095.00 | 1.85% | 1.11M | +425,245 | +61.9% | 2025-09-30 |